Table 2.
Results of univariate analysis for predicting local recurrence
| n | Local control rate | P value | ||
|---|---|---|---|---|
| Age | <64.5 | 46 | 0.855 | 0.889 |
| ≧64.5 | 27 | 0.830 | ||
| Tumor size | <4.0 | 17 | 0.933 | 0.267 |
| ≧4.0 | 56 | 0.819 | ||
| FIGO 2018 | I or II | 39 | 0.827 | 0.668 |
| III or IV | 34 | 0.865 | ||
| Histology | SCC | 61 | 0.838 | 0.599 |
| Others | 12 | 0.889 | ||
| EQD2 | <85 Gy | 64 | 0.824 | 0.213 |
| ≧85 Gy | 9 | 1.000 | ||
| RECIST | CR | 62 | 0.852 | 0.549 |
| PR | 11 | 0.818 | ||
| PERCIST | CMR | 58 | 0.896 | 0.013 |
| PMR or SMD | 15 | 0.667 | ||
| Metabolic response | CMR | 45 | 0.923 | 0.035 |
| PMR | 28 | 0.730 | ||
| Pre-treatment MTV | <73.3 | 50 | 0.910 | 0.031 |
| ≧73.3 | 23 | 0.712 | ||
| Pre-treatment SUVmax | <17.7 | 54 | 0.853 | 0.765 |
| ≧17.7 | 19 | 0.825 | ||
| Pre-treatment TLG | <703.6 | 57 | 0.902 | 0.014 |
| ≧703.6 | 16 | 0.641 | ||
| Post-treatment MTV | <5.0 | 56 | 0.932 | <0.001 |
| ≧5.0 | 17 | 0.588 | ||
| Post-treatment SUVmax | <4.2 | 65 | 0.909 | <0.001 |
| ≧4.2 | 8 | 0.375 | ||
| Post-treatment TLG | <15.1 | 65 | 0.909 | <0.001 |
| ≧15.1 | 8 | 0.375 |
SCC = squamous cell carcinoma, EQD2 = Equivalent Dose in 2 Gy fractions, CMR = complete metabolic response, PMR = partial metabolic response, SMD = stable metabolic disease